ReviewFrontiers in immunology2017
Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Effect of latent cytomegalovirus infection on the antibody response to influenza vaccination: a systematic review and meta-analysis.Medical microbiology and immunology · 2019Pooled it
- The effect of standard-dose wintertime vitamin D supplementation on influenza infection in immunized nursing home elderly residents.Croatian medical journal · 2021Trial
- Single-cell map of the healthy human immune system across the lifespan reveals unique infant immune signatures.Nature communications · 2026Article
- Pre-existing influenza antibodies, younger age, and increased CD4 THuman immunology · 2026Article
- Recent Trends in Cytomegalovirus IgG Seropositivity in the Adult Population of Korea: a Cross-Sectional Study and Literature Review.Annals of laboratory medicine · 2026Review
- Aging and vaccines: impact of immunosenescence and inflammaging in vaccine response.Frontiers in aging · 2026Review
- Ageing with HIV-1: immunological challenges for effective vaccination.Immunity & ageing : I & A · 2025Review
- Polymorphism in IFNλ Can Impact the Immune/Inflammatory Response to COVID-19 Vaccination in Older CMV-Seropositive Adults.Vaccines · 2025Article
- Vaccinations in older adults: Optimization, strategies, and latest guidelines.Journal of the American Geriatrics Society · 2025Article
- Impact of CMV latency on T-cell responses to COVID-19 vaccination among predominantly antibody-deficient patients.Frontiers in immunology · 2025Article
- DNA methylation clocks for estimating biological age in Chinese cohorts.Protein & cell · 2024Article
- A silver bullet for ageing medicine?: clinical relevance of T-cell checkpoint receptors in normal human ageing.Frontiers in immunology · 2024Review
- Spanish HCMV Seroprevalence in the 21st Century.Viruses · 2023Article
- Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly.Cell reports · 2023Article
- Ferrets as Models for Viral Respiratory Disease.Comparative medicine · 2023Review
- Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study.Open forum infectious diseases · 2023Article
- Coinfection and superinfection in ICU critically ill patients with severe COVID-19 pneumonia and influenza pneumonia: are the pictures different?Frontiers in public health · 2023Article
- Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly.Nature communications · 2022Article
- Aging and Microbiome in the Modulation of Vaccine Efficacy.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
The number of people over the age of 60 is expected to double by 2050 according to the WHO. This emphasizes the need to ensure optimized resilience to health stressors in late life. In older adults, influenza is one of the leading causes of catastrophic disability (defined as the loss of independence in daily living and self-care activities). Influenza vaccination is generally perceived to be less protective in older adults, with some studies suggesting that the humoral immune response to the vaccine is further impaired in cytomegalovirus (CMV)-seropositive older people. CMV is a β-herpes virus infection that is generally asymptomatic in healthy individuals. The majority of older adults possess serum antibodies against the virus indicating latent infection. Age-related changes in T-cell-mediated immunity are augmented by CMV infection and may be associated with more serious complications of influenza infection. This review focuses on the impact of aging and CMV on immune cell function, the response to influenza infection and vaccination, and how the current understanding of aging and CMV can be used to design a more effective influenza vaccine for older adults. It is anticipated that efforts in this field will address the public health need for improved protection against influenza in older adults, particularly with regard to the serious complications leading to loss of independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.